Peringatan Keamanan

Tallimustine is associated with myelotoxicity severe enough to stop its development.A182036,A182039

Tallimustine

DB15466

small molecule experimental

Deskripsi

Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.A182036,A182039 It's association with severe myelotoxicity lead to the end of its development in favour of ?-halogenoacrylamide derivatives such as brostallicin, which have a favourable cytotoxicity/myelotoxicity ratio.A182039,A182045 Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.A182051

Struktur Molekul 2D

Berat 697.62
Wujud -

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

39 Data
Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Tallimustine.
Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Tallimustine.
Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Tallimustine.
Methoxy polyethylene glycol-epoetin beta The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Tallimustine.
Lidocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Lidocaine.
Ropivacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Ropivacaine.
Bupivacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Bupivacaine.
Cinchocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Cinchocaine.
Dyclonine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Dyclonine.
Procaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Procaine.
Prilocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Prilocaine.
Proparacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Proparacaine.
Meloxicam The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Meloxicam.
Oxybuprocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Oxybuprocaine.
Cocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Cocaine.
Mepivacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Mepivacaine.
Levobupivacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Levobupivacaine.
Diphenhydramine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Diphenhydramine.
Benzocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Benzocaine.
Chloroprocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Chloroprocaine.
Phenol The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Phenol.
Tetrodotoxin The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Tetrodotoxin.
Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Benzyl alcohol.
Capsaicin The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Capsaicin.
Etidocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Etidocaine.
Articaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Articaine.
Tetracaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Tetracaine.
Propoxycaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Propoxycaine.
Pramocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Pramocaine.
Butamben The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Butamben.
Butacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Butacaine.
Oxetacaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Oxetacaine.
Ethyl chloride The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Ethyl chloride.
Butanilicaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Butanilicaine.
Metabutethamine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Metabutethamine.
Quinisocaine The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Quinisocaine.
Nelarabine The risk or severity of adverse effects can be increased when Nelarabine is combined with Tallimustine.
Ambroxol The risk or severity of methemoglobinemia can be increased when Tallimustine is combined with Ambroxol.
Etrasimod The risk or severity of immunosuppression can be increased when Tallimustine is combined with Etrasimod.

Target Protein

C-X-C chemokine receptor type 2 CXCR2
DNA

Referensi & Sumber

Synthesis reference: Cozzi P: The discovery of a new potential anticancer drug: a case history. Farmaco. 2003 Mar;58(3):213-20. doi: 10.1016/S0014-827X(03)00014-4.
Artikel (PubMed)
  • PMID: 11772279
    Marchini S, Broggini M, Sessa C, D'Incalci M: Development of distamycin-related DNA binding anticancer drugs. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. doi: 10.1517/13543784.10.9.1703 .
  • PMID: 12620417
    Cozzi P: The discovery of a new potential anticancer drug: a case history. Farmaco. 2003 Mar;58(3):213-20. doi: 10.1016/S0014-827X(03)00014-4.
  • PMID: 10919073
    Cozzi P: Recent outcome in the field of distamycin-derived minor groove binders. Farmaco. 2000 Mar;55(3):168-73.
  • PMID: 17691953
    Lauria A, Montalbano A, Barraja P, Dattolo G, Almerico AM: DNA minor groove binders: an overview on molecular modeling and QSAR approaches. Curr Med Chem. 2007;14(20):2136-60.
  • PMID: 30866557
    Paul A, Guo P, Boykin DW, Wilson WD: A New Generation of Minor-Groove-Binding-Heterocyclic Diamidines That Recognize G.C Base Pairs in an AT Sequence Context. Molecules. 2019 Mar 7;24(5). pii: molecules24050946. doi: 10.3390/molecules24050946.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul